Sun Pharma Q4 FY26 Earnings Call: Innovative Medicines Overtake Generics in US, Guides High Single-Digit Revenue Growth

Sun Pharmaceutical Industries Ltd held its Q4 FY26 earnings call on May 22, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Performance

• Consolidated sales of Rs.1,45,598 millionin Q4 FY2025-2026, up 13.6% YoY, with gross margin improving to 80.8% on better product mix.
• EBITDA of Rs.39,542 millionin Q4 FY2025-2026 (+6.4% YoY), with margin of 27.1% —down from 28.7% in Q4 FY2024-2025 and 31.9% in Q3 FY2025-2026.
• Reported net profit of Rs.27,140 millionin Q4 FY2025-2026; adjusted net profit of Rs.27,507 million; EPS of Rs.11.31.
• Full year FY2025-2026 EBITDA of Rs.1,77,314 million(+16.1%), margin of 30.3%; adjusted net profit of Rs.1,24,015 million.
• Board approved final dividend of Rs.5 per sharefor FY2025-2026, bringing total dividend for the year to Rs.16 per share (same as FY2024-2025).
• Effective tax rate of 22.3%in Q4 FY2025-2026 (vs. 19.8% in Q4 FY2024-2025 and 24.3% in Q3 FY2025-2026);forex gain of Rs.4,268 million partially offset margin compression.

Innovative Medicines Overtake Generics in the US

• US sales of $459 millionin Q4 FY2025-2026, down 1.1% YoY; full year FY2025-2026 US sales at $1.9 billion (marginal decline), contributing 28.8% of consolidated sales.
• Innovative medicines crossed $1.1 billionin the US for the first time in FY2025-2026, becoming the larger of the two US businesses (vs. generics);generic sales declined due to additional competition on certain products.
• Ilumya global sales of US$796 millionin FY2025-2026 (+16.7%); USFDA accepted BLA review for psoriatic arthritis with a regulatory action date of late October 2026 (FY2026-2027).
• Ilumya commercial presence expandedfrom 35 to 40 countries outside the US as of Q4 FY2025-2026; management expects continued Ilumya growth in FY2026-2027 supported by the submitted label extension.
• Levsalvi access improvedto majority coverage as of April 1, 2026 (FY2026-2027 start); management views new competition as market-expanding rather than threatening.
• Unlocks launchshowed positive physician receptivity due to PDL2 preservation reducing immune-mediated adverse events, with good uptake at cancer centers and repeat purchases.

Sustained Leadership and Broad-Based International Growth

• India formulation sales of Rs.48,359 millionin Q4 FY2025-2026 (+14.8% YoY); full year FY2025-2026 at Rs.1,92,904 million (+14%), representing 33.2% of total consolidated sales.
• Sun Pharma maintained #1 rankin the Indian pharmaceutical market with an 8.4% market share (Pharmatrac MAT March’26) vs 8.1% prior period — highest gain since the Ranbaxy acquisition.
• Volume growth of 6%in Q4 FY2025-2026 outpaced IPM volume growth of 1.6%; launched Semaglutide injection (Noveltrid/Sema Trinity) and 11 new products in India during the quarter.
• Emerging markets revenues of US$306 millionin Q4 FY2025-2026 (+17.4% YoY, constant currency 6.5%); full year at US$1.265 billion (+13.6%, CC 8.2%), driven by branded generics and Ilumya in Romania, Brazil, and China.
• ROW revenues of US$220 millionin Q4 FY2025-2026 (+10%); full year at US$969 million (+14.4%), contributing 13.8% of consolidated revenue, led by Ilumya and Odomzo.

Innovation R&D Share Set to Rise as Pipeline Expands

• Consolidated R&D spend of Rs.9,757 millionin Q4 FY2025-2026 (6.7% of sales), with innovative R&D comprising 36.9% of total R&D spend.
• R&D spend guided at 6–7% of revenuefor FY2026-2027, with the innovative R&D share expected to increase from the historical 40:60 split as the pipeline expands.
• Lexel V Phase 3 trial targeting adolescenceis active and ongoing (as of Q4 FY2025-2026); increase in intangible assets includes capitalization of Lexel V and checkpoint molecules.
• Oral semaglutide clinical study completed; launch is subject to regulatory approval. Initial market share data for injectable semaglutide in India is not yet reflective — management expects accurate data within 5–6 months (H2 FY2026-2027).
• Biosimilar discounts for Stellara reached ~90%in a different channel, but management stated this has not impacted Ilumya because it is reimbursed under Medicare Part B, which is not subject to negotiation or biosimilar-driven pricing changes.

Near-Term Margin Pressure with Mitigation Underway

• EBITDA margin declined to 27.1%in Q4 FY2025-2026 from 28.7% a year ago and 31.9% in Q3 FY2025-2026; CFO cited “relatively small” Revlimid impact and multiple small cost items, expecting normalization —no quantified guidance for FY2026-2027.
• Management declined to provide explicit EBITDA margin guidancefor FY2026-2027; expenses for Unloxet and Lexelvi launches have been factored into the FY2026-2027 plan.
• Effective tax rate for FY2026-2027 guided at 25%, up from 22.3% in Q4 FY2025-2026.
• New product launch promotional spend of ~$100 millionin FY2025-2026 was within guided range; management indicated such spend will become part of base brand investment going forward (FY2026-2027 onward), not a one-off.
• No large specialty launch in FY2026-2027; management will continue investing in Leqselvi and Winlevi as base spend, already factored into guidance —no sales from Leqselvi or Winlevi expected outside the US in FY2026-2027.
• U.S. President announced a “timeline for tariffs under Section 232 investigation on branded innovation drugs”with two dates in July and September; management is exploring mitigation options and doesnotexpect a negative impact in fiscal 2027.

Growth Framework Anchored by Organon and Pipeline Execution

• High single-digit consolidated top-line growth guidedfor FY2026-2027, based on current regulatory and macro-environment understanding.
• Organon acquisition expected to complete in Q4 FY2026-2027; integration management office set up and regulatory filings in progress. Management reiterated complementarity: ~50% of Organon’s established brands complement Sun’s branded generics; women’s health adds to innovative portfolio (now 26–27% of combined); biosimilars are a new addition; product overlaps described as “very negligible.”
• Generics business growth constrainedby compliance issues delaying approvals and ongoing pricing pressure; greenfield sterile-only facility in Madhya Pradesh addresses future volume expansion and capacity for global geographies.
• For MM2 (specialty dermatology), management confirmed a partnership strategy for the US market while self-marketing in emerging markets; for the type 2 diabetes drug, a similar approach is expected after Phase 2 completion.
• Balance sheet remains strongwith net cash of $3.2 billion at consolidated level.